Novartis AG

Compare

29 Followers

NOVN Stock Chart & Stats

CHF98.88

-CHF1.10(-1.10%)

At close: Mar 06 4:00 PM EST

CHF98.88

-CHF1.10(-1.10%)

Day’s Range― - ―

52-Week RangeCHF81.10 - CHF106.88

Previous CloseN/A

Volume858.75K

Average Volume (3M)2.71M

Market Cap

CHF188.17B

Enterprise ValueCHF208.96B

Total Cash (Recent Filing)CHF7.00B

Total Debt (Recent Filing)CHF32.64B

Price to Earnings (P/E)16.5

Beta0.91

Next Earnings

Feb 04, 2026

EPS Estimate

1.58

Last Dividend Ex-Date

Mar 11, 2025

Dividend Yield3.54%

Share Statistics

EPS (TTM)1.80

Shares Outstanding2,112,421,900

10 Day Avg. Volume2,438,245

30 Day Avg. Volume2,709,021

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF102.55

Price Target Upside3.71% Upside

Rating ConsensusHold

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

AcquisitionsNovartis is acquiring 3 key late-stage assets in neuromuscular disease and a technology platform of antibody oligonucleotide conjugates, offering significant growth potential.

Growth ProspectsThe acquisition allows Novartis to raise its mid-term sales growth forecast from 5% to 6%, reflecting increased confidence in future performance.

Product LaunchesKey product launches could lead to sales upgrades, including remibrutinib, ianalumab, Pluvicto, and Leqvio.

Bears Say

Earnings PerformanceNovartis reported a 3% miss in EPS with a 2% operational income miss, despite in-line sales driven by key growth drivers.

Growth OutlookFY25 sales and core operational income guides both unchanged, with implied core operational income guide below consensus, and slide suggesting slower growth outlook.

Short-Term Financial ImpactThe deal is expected to be 3-4% dilutive in the short term, impacting Novartis's core margin by 1-2%.

Novartis AG News

Novartis upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Novartis (NVS) to Overweight from Equal Weight with a price target of CHF 110, up...

1d ago

NVS

FDA moves to accelerate biosimilar development, lower drug costs

The U.S. Food and Drug Administration on Wednesday announced action to make it faster and less costly to...

2d ago

AZN

BMY

Novartis reports NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective

Novartis (NVS) presented new ianalumab data in Sjogren’s disease at a late-breaker presentation during the American College of...

3d ago

NVS

Tourmaline Bio acquisition completed by Novartis

Novartis (NVS) announced that it has successfully completed its acquisition of Tourmaline Bio (TRML). With the completion of...

4d ago

NVS

TRML

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

4d ago

NVS

Novartis announces expiration of Tourmaline Bio tender offer

Novartis (NVS) announced that its previously announced tender offer by Torino Merger Sub (TRML), a Delaware corporation and...

4d ago

NVS

TRML

Novartis price target raised to CHF 108 from CHF 105 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Novartis (NVS) to CHF 108 from CHF 105 and keeps...

5d ago

NVS

Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations

The major averages were sharply higher near noon as the market appears to exude new optimism amid fresh...

5d ago

Video: Merger Monday with deals announced in biotechnology and banking

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

5d ago

AWK

DYN

Avidity acquisition has positive read for Dyne Therapeutics, says Morgan Stanley

After Novartis (NVS) announced an agreement to acquire Avidity Biosciences (RNA), including its proprietary Antibody Oligonucleotide Conjugate platform...

5d ago

DYN

NVS

Positive Long-Term Growth Outlook for Novartis AG Amid Temporary Setbacks

In a report released today, Thibault Boutherin from Morgan Stanley upgraded Novartis AG to a Buy, with a...

1d ago

NVS

Cautious Hold Rating on Novartis AG Amid Mixed ianalumab Study Results and Uncertain Growth Prospects

In a report released today, Sachin Jain from Bank of America Securities maintained a Hold rating on Novartis...

5d ago

NVS

Novartis AG: Balancing Promising Growth Prospects with Policy and Market Challenges

Sachin Jain, an analyst from Bank of America Securities, maintained the Hold rating on Novartis AG. The associated...

1M ago

NVS

Novartis AG Faces Sell Rating Amid Overvaluation and Looming Generic Competition

In a report released today, James Quigley from Goldman Sachs downgraded Novartis AG to a Sell, with a...

2M ago

NVS

NOVN FAQ

What was Novartis AG’s price range in the past 12 months?

Novartis AG lowest stock price was CHF81.10 and its highest was CHF106.88 in the past 12 months.

What is Novartis AG’s market cap?

Novartis AG’s market cap is CHF188.17B.

When is Novartis AG’s upcoming earnings report date?

Novartis AG’s upcoming earnings report date is Feb 04, 2026 which is in 95 days.

How were Novartis AG’s earnings last quarter?

Novartis AG released its earnings results on Oct 28, 2025. The company reported CHF1.804 earnings per share for the quarter, missing the consensus estimate of CHF1.822 by -CHF0.018.

Is Novartis AG overvalued?

According to Wall Street analysts Novartis AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novartis AG pay dividends?

Novartis AG pays a Annually dividend of CHF3.5 which represents an annual dividend yield of 3.54%. See more information on Novartis AG dividends here

What is Novartis AG’s EPS estimate?

Novartis AG’s EPS estimate is 1.58.

How many shares outstanding does Novartis AG have?

Novartis AG has 2,112,421,900 shares outstanding.

What happened to Novartis AG’s price movement after its last earnings report?

Novartis AG reported an EPS of CHF1.804 in its last earnings report, missing expectations of CHF1.822. Following the earnings report the stock price went down -4.159%.

Which hedge fund is a major shareholder of Novartis AG?

Currently, no hedge funds are holding shares in CH:NOVN

Company Description

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG (NOVN) Earnings & Revenues

Historic Earnings Reports

NOVN Stock 12 Month Forecast

Average Price Target

CHF102.55

▲(3.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"CHF84","121":"CHF121","93.25":"CHF93.3","102.5":"CHF102.5","111.75":"CHF111.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF102.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF89.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,93.25,102.5,111.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.02,105.24923076923076,106.47846153846153,107.7076923076923,108.93692307692308,110.16615384615385,111.39538461538461,112.62461538461538,113.85384615384615,115.08307692307692,116.31230769230768,117.54153846153847,118.77076923076923,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.02,103.90692307692308,103.79384615384615,103.68076923076923,103.5676923076923,103.45461538461538,103.34153846153846,103.22846153846153,103.11538461538461,103.0023076923077,102.88923076923076,102.77615384615385,102.66307692307691,{"y":102.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.02,102.86461538461538,101.70923076923077,100.55384615384615,99.39846153846153,98.24307692307693,97.08769230769231,95.93230769230769,94.77692307692308,93.62153846153846,92.46615384615384,91.31076923076924,90.15538461538462,{"y":89,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":93.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.92,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.29,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.79,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >